Benazepril causes in hypertension a greater reduction in left ventricular mass than does nitrendipine: A randomized study using magnetic resonance imaging

Journal of Cardiovascular Pharmacology

Volumn 32, Issue 5, 1998, Pages 760-768

  Gaudio, C ^a,c   Tanzilli, G ^a   Ferri, F M ^a   Villatico Campbell, S ^a   Bertocchi, F ^b   Motolese, M ^a   Campa, P P ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Medical Department   (Italy)

^c NONE   (Italy)

Author keywords

Benazepril; Echocardiography; Left ventricular hypertrophy regression; Magnetic resonance imaging; Nitrendipine

Indexed keywords

BENAZEPRIL; NITRENDIPINE; PLACEBO;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SINGLE BLIND PROCEDURE;

ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZAZEPINES; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; ECHOCARDIOGRAPHY; FEMALE; HEART RATE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NITRENDIPINE; PROSPECTIVE STUDIES; VENTRICULAR FUNCTION, LEFT;

EID: 0031763493     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199811000-00012     Document Type: Article

References (52)

1. Folkow B. The Fourth Volhaard Lecture: cardiovascular structural adaptation - its role in initiation and maintenance of primary hypertension. Clin Sci Mol Med 1987;55:53-22.
2. Grossman W. Cardiac hypertrophy: useful adaptation or pathologic process? Am J Med 1980;69:576-84.
3. Kannel WB, Levy D, Cupples LA. Left ventricular hypertrophy and risk of cardiac failure: insight from the Framingham study. J Cardiovasc Pharmacol 1987;10:S135-40.
4. McLenachan JM, Henderson E, Morris KL, Dargie HJ. Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy. N Engl J Med 1987;317:787-92.
5. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561-6.
6. Koren MJ, Ulin RJ, Laragh JH, Devereux RB. Reduction of left ventricular mass during treatment of essential hypertension is associated with improved prognosis [Abstract]. Am J Hypertens 1991;4:1A.
7. Yurenev AP, Dyakonova HG, Novikov ID, et al. Management of essential hypertension in patients with different degrees of left ventricular hypertrophy: multicentre trial. Am J Hypertens 1992;5(suppl): S182-9.
8. Levy D, Salomon M, D'Agostino RB, Belanger AJ, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994;90:1786-93.
9. Muiesan ML, Salvetti M, Rizzoni D, Castellano M, Donato F, Agabiti-Rosei E. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens 1995;13:1091-105.
10. Verdecchia P, Schillaci G, Borgioni C, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998;97:48-54.
11. Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: a meta-analysis of 109 treatment studies. Am J Hypertens 1992;5:95-110.
12. Cruickshank J, Lewis J, Moore V, Dodd C. Reversibility of left ventricular hypertrophy by different types of antihypertensive therapy. J Hum Hypertens 1992;6:85-90.
13. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: meta-analysis of randomized double-blind studies. JAMA 1996;275:1507-13.
14. Keller MA, Peshock RM, Malloy CR, et al. In vivo measurement of myocardial mass using nuclear magnetic resonance imaging. J Am Coll Cardiol 1986;8:113-7.
15. Maddahi J, Crues J, Berman DS, et al. Noninvasive quantification of left ventricular myocardial mass by gated proton nuclear magnetic resonance imaging. J Am Coll Cardiol 1987;10:682-92.
16. Dilworth LR, Aisen AM, Mancini GBJ, Lande I, Buda AJ. Determination of left ventricular volumes and ejection fraction by nuclear magnetic resonance imaging. Am Heart J 1987;113:24-32.
17. Higgins CB, Holt W, Pflugfelder P, Sechtem U. Functional evaluation of the heart with magnetic resonance imaging. Magn Reson Med 1988;6:121-39.
18. Longmore D, Forbat S. Studies of the heart using magnetic resonance. J Cardiovasc Pharmacol 1992;19(suppl 1):S87-111.
19. Eichstaedt H, Danne O, Langer M, et al. Regression of LVH under ramipril treatment investigated by nuclear magnetic resonance imaging. J Cardiovasc Pharmacol 1989;13(suppl 3):S75-80.
20. Gaudio C, Tanzilli G, Mazzarotto P, et al. Comparison of left ventricular ejection fraction by magnetic resonance imaging and radionuclide ventriculography in idiopathic dilated cardiomyopathy. Am J Cardiol 1991;67:411-5.
21. Gaudio C, Tanzilli G, Collatina S, Pagnotta P, Paknejad K, Campa PP. Evaluation of regression of left ventricular hypertrophy in hypertensive patients treated with captopril as assessed by magnetic resonance imaging. Cardiologia 1992;37:789-91.
22. Missouris CG, Forbat SM, Singer RJ, Markandu ND, Underwood R, MacGregor G. Echocardiography overestimates left ventricular mass: a comparative study with magnetic resonance imaging in patients with hypertension. J Hypertens 1996;14:1005-10.
23. Hansson L, Hedner T, Dahlof B. Prospective, Randomized, Open Blinded Endpoint (PROBE) study: a novel design for intervention trials. Blood Press 1992;1:113-9.
24. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurements. Lancet 1986;1:307-10.
25. Katz J, Milliken MC, Stray-Gundersen J, et al. Estimation of human myocardial mass with MRI. Radiology 1988;169:495-8.
26. Ostrzega E, Maddahi J, Honma H, et al. Quantification of left ventricular myocardial mass in humans by nuclear magnetic resonance imaging. Am Heart J 1989;117:444-52.
27. Shan DJ, DeMaria A, Kisslo J, Weymann A. The Committee on M-Mode Standardization of the American Society of Echocardiography: recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978;58:1072-83.
28. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986;57:450-8.
29. Gottdiener JS, Reda DJ, Massie BM, Materson BJ, Williams DW, Anderson RJ. Effect of single-drug therapy on reduction of left ventricular mass in moderate hypertension: comparison of six antihypertensive agents. Circulation 1997;95:2007-14.
30. Fagard R, Lijnen P, Staessen J, Thijs L, Amery A. Mechanical and other factors relating to left ventricular hypertrophy. Blood Press 1994;3(suppl 1):5-10.
31. Ferrara LA, Fasano ML, de Simone G, Soro S, Gagliardi R. Antihypertensive and cardiovascular effects of nitrendipine: a controlled study vs placebo. Clin Pharmacol Ther 1985;38:434-8.
32. Giles TD, Sander GE, Roffidal LC, Thomas MG, Given MB, Quiroz AC. Comparison of nitrendipine and hydrochlorothiazide for systemic hypertension. Am J Cardiol 1987;60:103-6.
33. Grossman E, Oren S, Garavaglia GE, Messerli F, Frolich ED. Systemic and regional hemodynamic and humoral effects of nitrendipine in essential hypertension. Circulation 1988;78:1394-400.
34. Vogt M, Kreutz KU, Motz W, Strauer BE. Hypertrophieregression nach nitrendipin: einfluss auf systoliche und diastolische function. Z Cardiol 1989;78:469-77.
35. Agabiti-Rosei E, Muiesan ML, Rizzoni D, Romanelli G, Beschi M, Castellano M. Regression of cardiovascular structural changes after long-term antihypertensive treatment with the calcium-antagonist nitrendipine. J Cardiovasc Pharmacol 1991;18(suppl 5):S5-9.
36. Lopez NC, Corral JL, Rincon LA, et al. Nitrendipine and atenolol in essential hypertension in young and middle-aged patients: effect on serum lipids and left ventricular mass. J Cardiovasc Pharmacol 1991;18(suppl 1):S101-5.
37. Drayer JIM, Hall WD, Smith VE, Weber MA, Wollam GL, White WB. Effect of the calcium channel blocker nitrendipine on left ventricular mass in patients with hypertension. Clin Pharmacol Ther 1986;40:679-85.
38. Messerli FH, Oren S, Grossman E. Left ventricular hypertrophy and antihypertensive therapy. Drugs 1988;35(suppl 5):27-33.
39. Gaudio C, Miccheli A, Ricci R, Pizzuto F, Puddu PE, Reale A. Angulated transverse tomographic sections to measure cardiac dimension by magnetic resonance imaging: a comparison with 2D-echocardiography. Cardiologia 1989;6:513-6.
40. Schillaci G, Verdecchia P, Porcellati C. Does echocardiography overestimate left ventricular mass? J Hypertens 1997;15:213-4.
41. Devereux RB, Pini R, Aungemma GP, Roman MJ. Measurement of left ventricular mass: methodology and expertise. J Hypertens 1997;15:801-9.
42. Porcellati C, Verdecchia P, Schillaci G, Boldrini F, Motolese M. Long-term effects of benazepril on ambulatory blood pressure, left ventricular mass, diastolic filling and aortic flow in essential hypertension. Int J Clin Pharmacol 1991;29:187-97.
43. Corea L, Bentivoglio M, Buccolieri M, Savino K, Zollino L, Motolese M. Beneficial effect of benazepril on left ventricular mass in hypertension. High Blood Press 1996;5:21-7.
44. Muiesan ML, Agabiti-Rosei E, Romanelli G, Alari G, Barbier P, Fiorentini C. Left ventricular systolic function in relation to withdrawal of different treatments in hypertensives with left ventricular hypertrophy. J Hypertens 1988;6(suppl 4):S97-100.
45. Trimarco B, De Luca N, Ricciardelli B, et al. Cardiac function in systemic hypertension before and after reversal of left ventricular hypertrophy. Am J Cardiol 1988;64:745-50.
46. Schmieder RE, Messerli FH, Sturgill D, Garavaglia GE, Nunez BD. Cardiac performance after reduction of myocardial hypertrophy. Am J Med 1989;87:22-7.
47. Muiesan ML, Agabiti-Rosei E, Romanelli G, et al. Improved left ventricular systolic and diastolic function after regression of cardiac hypertrophy, treatment withdrawal and redevelopment of hypertension. J Cardiovasc Pharmacol 1991;17(suppl 2):S179-81.
48. Gonzales-Juanatey JR, Pose Reino A, Garcia Acuna JM, et al Left ventricular systolic function after marked reduction of ventricular hypertrophy induced by 5 years' enalapril treatment Eur Heart J 1995;16:1981-7.
49. Shahi M, Thorn S, Poulter N, Sever PS, Foale RA. Regression of hypertensive left ventricular hypertrophy and left ventricular diastolic function. Lancet 1990;336:458-61.
50. Bielen EC, Fagard RH, Lijnen PJ, Tjandra-Maga T, Verbesselt R, Amery AK. Comparison of the effects of isradipine and lisinopril on left ventricular structure and function in essential hypertension. Am J Cardiol 1992;69:1200-6.
51. Omotoso AB, Dunn FG. Impact of regression of left ventricular hypertrophy on cardiac function in hypertension. Eur Heart J 1992;13(suppl D):107-10.
52. Fagard RH, Lijnen P. Reduction of left ventricular mass by antihypertensive treatment does not improve exercise performance in essential hypertension. J Hypertens 1997;15:309-17.